$495 Million is the total value of Opaleye Management Inc.'s 48 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NLTX | NEOLEUKIN THERAPEUTICS INC | $23,240,000 | +45.9% | 1,400,000 | 0.0% | 4.69% | +11.2% | |
| CCXI | CHEMOCENTRYX INC | $20,816,000 | +43.3% | 361,600 | 0.0% | 4.20% | +9.2% | |
| ETON | ETON PHARMACEUTICALS INC | $19,838,000 | +32.9% | 3,640,000 | 0.0% | 4.01% | +1.3% | |
| CDXS | CODEXIS INC | $16,089,000 | +3.0% | 1,400,000 | 0.0% | 3.25% | -21.5% | |
| EIDX | EIDOS THERAPEUTICS INC | $14,634,000 | -5.3% | 315,550 | 0.0% | 2.96% | -27.9% | |
| DCPH | DECIPHERA PHARMACEUTICALS IN | $13,081,000 | +43.1% | 222,000 | 0.0% | 2.64% | +9.1% | |
| ATXI | AVENUE THERAPEUTICS INC | $11,147,000 | +20.5% | 1,035,000 | 0.0% | 2.25% | -8.2% | |
| FGEN | FIBROGEN INC | $5,688,000 | +12.1% | 146,000 | 0.0% | 1.15% | -14.6% | |
| AMRN | AMARIN CORP PLCsponsored adr | $3,149,000 | +73.0% | 455,000 | 0.0% | 0.64% | +32.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.